On behalf of FDA Commissioner Marty Makary, M.D., M.P.H., the FDA is holding a series of roundtable discussions with independent panels of scientific experts that will review the latest scientific evidence, evaluate potential health risks, explore safer alternatives, and may offer recommendations for regulatory action. This initiative is part of the FDA’s broader efforts to apply| RxISK - Making Medicines Safer for All of Us
In 2023 a new set of Canadian Guidelines for the Management of Alcohol Use Disorders put a serious problem on the radar for doctors that few of them likely expected. See Antidepressants, Alcohol and Anne-Marie. The antidepressants doctors commonly prescribed, often telling people these medicines would help them manage their alcohol issues, were likely causing| RxISK - Making Medicines Safer for All of Us
The Serotonin Reuptake Inhibitor (SRI) story starts in 1969 with Arvid Carlsson (above) who created Zelmid, the first SRI, after listening to people on antidepressants. He linked an anxiolytic effect some older drugs have to the serotonin system. The SRIs aimed at exploring that effect - Normality and Antidepressant Dysregulation. Fluoxetine (Prozac). sertraline (Zoloft). paroxetine| RxISK - Making Medicines Safer for All of Us